Please assess the completion status of the following clinical trial:

Trial Title: Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed non-small-cell bronchogenic carcinoma (squamous carcinoma, adenocarcinoma, or large cell carcinoma). Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable. Mixed tumors with small-cell anaplastic elements are not eligible.~2. Patients who have newly diagnosed unresectable stage III or IV disease are eligible. Patients with stage III disease should be ineligible for combined modality therapy~3. Patients must not have received any prior antineoplastic chemotherapy for metastatic lung cancer prior to study entry.~4. Patients who have had previous radiotherapy as definitive therapy for locally advanced non-small-cell are eligible as long as the recurrence is outside the original radiation port. Radiation therapy must have been completed greater than 4 weeks prior to registration.~5. Male or female patients \>=18 years of age.~6. Life expectancy of at least 3 months.~7. ECOG performance status of \<=1.~8. Measurable disease by RECIST criteria (see Section 7).~9. Laboratory values as follows:~   * ANC \>=1500/mm3 (7 days prior to treatment);~  * Hemoglobin \>=8 g/dL;~  * Platelets \>=100,000 mm3 (7 days prior to treatment)~  * Bilirubin \<=1 x ULN for institution~  * AST/SGOT \<=2.5 x ULN or \<=5.0 x ULN in patients with liver metastases and~  * ALT/SGPT \<=2.5 x ULN or \<=5.0 x ULN in patients with liver metastases~  * Creatinine \<=2.0 mg/dL or~  * Calculated (measured) GFR \>=40 mL/min~  * PT/INR and PTT \<=1.5 x ULN~10. Peripheral neuropathy \<= grade 1.~Exclusion Criteria:~1. A history of cardiac disease as defined by malignant hypertension, unstable angina, congestive heart failure of \> grade 2 per New York Heart Association (NYHA) criteria (see Appendix B), myocardial infarction within the previous 6 months, or symptomatic cardiac arrhythmias.~2. Metastatic brain or meningeal tumors.~3. Uncontrolled intercurrent illness.~4. Chemotherapy, investigational drug therapy, or major surgery ≤ 4 weeks prior to starting study drug, or patients who have not recovered from side effects of previous therapy.~5. Patient is \<=5 years free of another primary malignancy, except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ.~Exclusion Criteria for Enrollment on Bevacizumab (Cohort B):~1. Patients with squamous cell histology NSCLC.~2. Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury within 1 month of beginning bevacizumab.~3. Patients who have had primary thoracic radiation within 3 months of beginning bevacizumab.~4. Fine needle aspiration, core biopsy, mediastinoscopy or other minor surgical procedure within 7 days of beginning bevacizumab.~5. Patients receiving thrombolytic therapy within 10 days of starting bevacizumab.~6. Patients with serious non-healing wound, ulcer, or bone fracture.~7. Patients with evidence of bleeding diathesis or coagulopathy.~8. Patients with history of hemoptysis (defined as bright red blood of ½ teaspoon or more per episode) within 3 months prior to study enrollment.~9. Patients with proteinuria at screening, as demonstrated by either:~   * Urine protein : creatinine (UPC) ratio \>=1.0 or~  * Urine dipstick for protein \>=2+ (patients discovered to have \>=2+ proteinuria on dipstick at baseline should undergo a 24-hour urine collection, and must demonstrate \<1 g of protein in 24 hours to be eligible).~10. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
- Cohort B (Type: EXPERIMENTAL): ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).